Exagen (XGN) Cost of Revenue (2018 - 2026)
Exagen filings provide 9 years of Cost of Revenue readings, the most recent being $7.1 million for Q1 2026.
- On a quarterly basis, Cost of Revenue rose 11.39% to $7.1 million in Q1 2026 year-over-year; TTM through Mar 2026 was $28.5 million, a 23.45% increase, with the full-year FY2025 number at $27.8 million, up 23.29% from a year prior.
- Cost of Revenue hit $7.1 million in Q1 2026 for Exagen, down from $7.4 million in the prior quarter.
- In the past five years, Cost of Revenue ranged from a high of $7.4 million in Q4 2025 to a low of $5.2 million in Q4 2024.
- Median Cost of Revenue over the past 5 years was $6.0 million (2024), compared with a mean of $6.2 million.
- Biggest five-year swings in Cost of Revenue: decreased 10.92% in 2023 and later skyrocketed 43.4% in 2025.
- Exagen's Cost of Revenue stood at $6.3 million in 2022, then fell by 10.92% to $5.6 million in 2023, then decreased by 7.86% to $5.2 million in 2024, then skyrocketed by 43.4% to $7.4 million in 2025, then decreased by 4.36% to $7.1 million in 2026.
- The last three reported values for Cost of Revenue were $7.1 million (Q1 2026), $7.4 million (Q4 2025), and $7.2 million (Q3 2025) per Business Quant data.